Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
antidepressant |
| gptkbp:activeIngredient |
gptkb:venlafaxine
|
| gptkbp:approvalYear |
1993
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
gptkb:N06AX16
|
| gptkbp:contraindication |
MAOI use
|
| gptkbp:drugClass |
norepinephrine reuptake inhibitor
|
| gptkbp:eliminationHalfLife |
5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:tablet
extended-release capsule |
| gptkbp:genericAvailable |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Effexor
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
gptkb:discontinuation_syndrome
gptkb:serotonin_syndrome hypertension |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness sweating insomnia dry mouth sexual dysfunction |
| gptkbp:usedFor |
gptkb:generalized_anxiety_disorder
gptkb:panic_disorder gptkb:social_anxiety_disorder gptkb:major_depressive_disorder |
| gptkbp:bfsParent |
gptkb:Wyeth
|
| gptkbp:bfsLayer |
5
|